The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. Read the full story

Alder BioPharmaceuticals has regained the worldwide pharma licensing rights to clazakizumab, a humanized monoclonal antibody to the pro-inflammatory cytokine IL-6, from Bristol-Myers Squibb Read the full story

Pfizer and Merck & Co announced a clinical trial biotech partnering deal to test Merck’s Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizer’s Crizotinib (XALKORI) in combination for patients with ALK-positive advanced or metastatic non-small cell lung cancer. Read the full story

EirGenix has signed the agreement with TaiMed Biologics to provide development and manufacturing services for TaiMed’s second generation anti-HIV monoclonal antibody, TMB-360. Read the full story

Monoclonal antibodies are developed to be very selective in targeting cells. This is why they have come to be an indispensable research tool in cancer treatment being able to specifically target tumor cells.

Read the full story

A recent market research analysis of monoclonal antibody partnering has shown a high interest in partnering deals involving monoclonal antibody technology in the past few years Read the full story

Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are the same because they are made... Read the full story

Immunomedics has received notification from Takeda, big pharma company, of the termination of the licensing pharma partnership agreement signed between Nycomed GmbH and Immunomedics for the worldwide rights to veltuzumab, the humanized anti-CD20 antibody, for all non-cancer indications Read the full story

GlaxoSmithKline , a big pharma company, announced a new four year contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services , for the provision of its inhalation anthrax treatment, raxibacumab, forming biopharma partners Read the full story

Ultragenyx Pharmaceutical has entered into pharma deals with Kyowa Hakko Kirin, to develop and commercialize KRN23. Read the full story